Tianjin Development Holdings ( ($HK:0882) ) has shared an update. Tianjin Development Holdings Limited announced the audited financial results for
Tianjin Lisheng Pharmaceutical Co., Ltd. has announced its financial results for the year 2024, revealing a significant increase in both revenue and net profit. The company reported a revenue growth of 15.6% year-over-year, driven by strong demand for its pharmaceutical products, particularly in the cardiovascular and anti-infective segments. Net profit saw an even more impressive rise, up by 23.4%, attributed to enhanced operational efficiencies and cost management strategies. Additionally, the board proposed a dividend of RMB 0.50 per share, reflecting confidence in the company's financial health and future prospects. This proposal is subject to shareholder approval at the upcoming annual general meeting. The company also highlighted its ongoing investments in research and development, aiming to expand its product portfolio and strengthen its market position both domestically and internationally.
Automotive & Transportation
